Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Equity Average (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Equity Average for 15 consecutive years, with $937.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 35.0% year-over-year to $937.3 million, compared with a TTM value of $937.3 million through Dec 2025, up 35.0%, and an annual FY2025 reading of $841.0 million, up 50.77% over the prior year.
  • Equity Average was $937.3 million for Q4 2025 at Catalyst Pharmaceuticals, up from $888.1 million in the prior quarter.
  • Across five years, Equity Average topped out at $937.3 million in Q4 2025 and bottomed at $174.1 million in Q1 2021.
  • Average Equity Average over 5 years is $447.1 million, with a median of $358.2 million recorded in 2023.
  • The sharpest move saw Equity Average rose 22.63% in 2022, then skyrocketed 88.55% in 2024.
  • Year by year, Equity Average stood at $202.7 million in 2021, then soared by 40.68% to $285.2 million in 2022, then rose by 29.09% to $368.2 million in 2023, then surged by 88.55% to $694.3 million in 2024, then surged by 35.0% to $937.3 million in 2025.
  • Business Quant data shows Equity Average for CPRX at $937.3 million in Q4 2025, $888.1 million in Q3 2025, and $825.2 million in Q2 2025.